Graham Baker - Smith Nephew CFO, Executive Director
SNNUF Stock | USD 12.39 0.31 2.57% |
Director
Mr. Graham Baker is Chief Financial Officer, Executive Director of the Company. He joined the Board as Chief Financial Officer in March 2017. He is based in London, UK. Career and experience Graham holds an MA degree in Economics from Cambridge University and qualified as a Chartered Accountant and Chartered Tax Adviser with Arthur Andersen. In 1995, he joined AstraZeneca PLC where he worked for 20 years, holding multiple senior roles, including Vice President Finance Chief Financial Officer, North America, Vice President, Global Financial Services and Vice President, Finance, International 20132015 with responsibility for all emerging markets. Most recently, Graham was Chief Financial Officer of generic pharmaceuticals company Alvogen. Skills and competencies Graham has deep sector knowledge and has had extensive exposure to established and emerging markets which is extremely relevant to his role at Smith Nephew. He has a strong track record of delivering operational excellence and has relevant experience across major finance roles and geographic markets, leading large teams responsible for significant budgets. since 2017.
Age | 49 |
Tenure | 7 years |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Susan Knight | SurModics | 63 | |
David Deming | PetVivo Holdings | 60 | |
Kenneth Ludlum | IRIDEX | 63 | |
David Merrill | PetVivo Holdings | 68 | |
ChihHeng Lu | Ainos Inc | 44 | |
John Dolan | PetVivo Holdings | 59 | |
Robert Grove | IRIDEX | N/A | |
Lisa Heine | SurModics | 54 | |
Jose Bedoya | SurModics | 61 | |
Maria Sainz | IRIDEX | 52 | |
Shawn McCormick | SurModics | 53 | |
Robert Rudelius | PetVivo Holdings | 61 | |
Ronald Kalich | SurModics | 70 | |
Ruediger NaumannEtienne | IRIDEX | 71 | |
Scott Shuda | IRIDEX | 52 | |
David Dantzker | SurModics | 74 | |
Sherry Grisewood | PetVivo Holdings | N/A | |
Randall Meyer | PetVivo Holdings | 60 | |
Joseph Jasper | PetVivo Holdings | N/A | |
John Benson | SurModics | 69 | |
Sanford Fitch | IRIDEX | 76 |
Management Performance
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 |
Smith Nephew plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Namal Nawana, CEO, Executive Director | ||
Michael Friedman, Non-Executive Independent Director | ||
Diogo MoreiraRato, President - Europe and Canada | ||
Alison Parkes, Chief Officer | ||
Skip Kiil, President - Orthopedics | ||
Erik Engstrom, Non-Executive Director | ||
Deepak Nath, CEO Director | ||
Matthew Stober, President - Global Operations | ||
Marc Owen, Non-Executive Director | ||
AnneFrancoise Nesmes, CFO Director | ||
Helen Barraclough, Company Counsel | ||
Rodrigo Bianchi, President IRAMEA | ||
Brian Larcombe, Senior Independent Non-Executive Director | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, Sports Orthopaedics | ||
Gunthorp Oie, IR Contact Officer | ||
Roland Diggelmann, Non-Executive Director | ||
Helen Maye, Chief Human Resources Officer | ||
Vinita Bali, Non-Executive Director | ||
Simon Fraser, President - Advanced Wound Management | ||
Massimiliano Colella, President Europe - Middle East and Africa | ||
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
Graham Baker, CFO, Executive Director | ||
Cathy ORourke, Chief Legal and Compliance Officer | ||
Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
Joe Metzger, VP Communications | ||
Cyrille Petit, Chief Corporate Development Officer | ||
Julie Brown, CFO, Director and Member of Disclosures Committee | ||
Glenn Warner, President - Advanced Wound Management | ||
Robin Freestone, Non-Executive Director | ||
Paul Connolly, Pres Operations | ||
Virginia Bottomley, Non-Executive Independent Director | ||
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
Angie Risley, Non-Executive Director | ||
Mark Gladwell, President - Global Operations | ||
Andrew Swift, VP Relations | ||
Vasant Padmanabhan, President - Research & Development | ||
Michael Frazzette, President - Advanced Surgical Devices | ||
Joseph Papa, Non-Executive Independent Director | ||
Ingeborg Oie, VP, Investor Relations | ||
Susan Swabey, Company Secretary | ||
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
Philip Cowdy, Chief Officer | ||
Gordon Howe, President of Global Operations | ||
John Campo, Chief Legal Officer | ||
Brad Cannon, President Europe and Canada | ||
Ian Barlow, Non-Executive Independent Director | ||
Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 | |||
Profit Margin | 0.1 % | |||
Operating Margin | 0.14 % | |||
Current Valuation | 14.08 B | |||
Shares Outstanding | 873.35 M | |||
Shares Owned By Insiders | 0.17 % | |||
Shares Owned By Institutions | 52.60 % | |||
Price To Earning | 23.41 X | |||
Price To Book | 2.12 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |